Collectively, these findings highlight the therapeutic promise of targeting the CD47-SIRPα axis, particularly when combined with PD-1 blockade, to enhance anti-tumor immunity and overcome resistance mechanisms in cHL [111,112,113]. The gene discussed is SIRPA; the disease is neoplasm.